Elevated plasma high-mobility group box 1 protein is a potential marker for neuromyelitis optica

Neuroscience

Volumn 226, Issue , 2012, Pages 510-516

  Wang, K C ^a,b,c   Tsai, C P ^b,c   Lee, C L ^c,d   Chen, S Y ^e   Chin, L T ^a,f   Chen, S J ^a,g  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b CHENG HSIN GENERAL HOSPITAL   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e CARDINAL TIEN HOSPITAL   (Taiwan)

^f NATIONAL CHIAYI UNIVERSITY   (Taiwan)

^g TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Cytokine; ELISA; High mobility group box 1 protein; Multiple sclerosis; Neuromyelitis optica

Indexed keywords

GAMMA INTERFERON; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 17; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MOLECULAR DIAGNOSIS; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ADULT; AGE OF ONSET; AQUAPORIN 4; AREA UNDER CURVE; AZATHIOPRINE; BIOLOGICAL MARKERS; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HMGB1 PROTEIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROMYELITIS OPTICA; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; ROC CURVE;

EID: 84868273388     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2012.08.041     Document Type: Article

References (42)

1. Andersson A., Covacu R., Sunnemark D., Danilov A.I., Dal Bianco A., Khademi M., Wallström E., Lobell A., Brundin L., Lassmann H., Harris R.A. Pivotal advance: HMGB1 expression in active lesions of human and experimental multiple sclerosis. J Leukoc Biol 2008, 84:1248-1255.
2. Andersson U., Wang H., Palmblad K., Aveberger A.C., Bloom O., Erlandsson-Harris J., Janson A., Kokkola R., Zhang M., Yang H., Tracey K.J. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 2000, 192:565-570.
3. Bonaldi T., Talamo F., Scaffidi P., Ferrera D., Porto A., Bachi A., Rubartelli A., Agresti A., Bianchi M.E. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J 2003, 22:5551-5560.
4. Bustin M. Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol Cell Biol 1999, 19:5237-5246.
5. Cabre P., González-Quevedo A., Bonnan M., Saiz A., Olindo S., Graus F., Smadja D., Merle H., Thomas L., Cabrera-Gomez J.A. Relapsing neuromyelitis optica: long term history and clinical predictors of death. J Neurol Neurosurg Psychiatry 2009, 80:1162-1164.
6. Cornelio D.B., Braga R.P., Rosa M.W., Ayub A.C. Devic's neuromyelitis optica and pregnancy: distinction from multiple sclerosis is essential. Arch Gynecol Obstet 2009, 280:475-477.
7. Cree B. Neuromyelitis optica: diagnosis, pathogenesis, and treatment. Curr Neurol Neurosci Rep 2008, 8:427-433.
8. de Seze J., Lebrun C., Stojkovic T., Ferriby D., Chatel M., Vermersch P. Is Devic's neuromyelitis optica a separate disease? A comparative study with multiple sclerosis. Mult Scler 2003, 9:521-525.
9. Dumitriu I.E., Baruah P., Valentinis B., Voll R.E., Herrmann M., Nawroth P.P., Arnold B., Bianchi M.E., Manfredi A.A., Rovere-Querini P. Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol 2005, 174:7506-7515.
10. Gupta R., Sheikh A., Strachan D.P., Anderson H.R. Burden of allergic disease in the UK: secondary analyses of national databases. Clin Exp Allergy 2004, 34:520-526.
11. Han J., Zhong J., Wei W., Wang Y., Huang Y., Yang P., Purohit S., Dong Z., Wang M.H., She J.X., Gong F., Stern D.M., Wang C.Y. Extracellular high-mobility group box 1 acts as an innate immune mediator to enhance autoimmune progression and diabetes onset in NOD mice. Diabetes 2008, 57:2118-2127.
12. Hazin R., Khan F., Bhatti M.T. Neuromyelitis optica: current concepts and prospects for future management. Curr Opin Ophthalmol 2009, 20:434-439.
13. Hummers L.K., Krishnan C., Casciola-Rosen L., Rosen A., Morris S., Mahoney J.A., Kerr D.A., Wigley F.M. Recurrent transverse myelitis associates with anti-Ro (SSA) autoantibodies. Neurology 2004, 62:147-149.
14. Kimura R., Shiibashi R., Suzuki M., Hayashizaki Y., Chiba J. Enhancement of antibody response by high mobility group box protein-1-based DNA immunization. J Immunol Methods 2010, 361:21-30.
15. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452.
16. Lai C.H., Tseng H.F. Population-based epidemiological study of neurological diseases in Taiwan: I. Creutzfeldt-Jakob disease and multiple sclerosis. Neuroepidemiology 2009, 33:247-253.
17. Lennon V.A., Wingerchuk D.M., Kryzer T.J., Pittock S.J., Lucchinetti C.F., Fujihara K., Nakashima I., Weinshenker B.G. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004, 364:2106-2112.
18. Leslie S.J., Johnston N., Strachan F.E., Bagnali A., Gray G.A., Newby D.E., Denvir M.A., Webb D.J. Endothelin-1[1-31] is not elevated in men with chronic heart failure. J Cardiovasc Pharmacol 2004, 44(Suppl. 1):S96-S99.
19. Li B., Kawatkar S.P., George S., Strachan H., Woods R.J., Siriwardena A., Moremen K.W., Boons G.J. Inhibition of Golgi mannosidase II with mannostatin A analogues: synthesis, biological evaluation, and structure-activity relationship studies. Chembiochem 2004, 5:1220-1227.
20. Lin W., Kemper A., Dupree J.L., Harding H.P., Ron D., Popko B. Interferon-gamma inhibits central nervous system remyelination through a process modulated by endoplasmic reticulum stress. Brain 2006, 129(Pt. 5):1306-1318.
21. Marioni R.E., Deary I.J., Strachan M.W., Lowe G.D., Rumley A., Murray G.D., Price J.F. Blood rheology and cognition in the Edinburgh Type 2 Diabetes Study. Age Ageing 2010, 39:354-359.
22. Matsuoka T., Matsushita T., Kawano Y., Osoegawa M., Ochi H., Ishizu T., Minohara M., Kikuchi H., Mihara F., Ohyagi Y., Kira J. Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain 2007, 130:1206-1223.
23. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., McFarland H.F., Paty D.W., Polman C.H., Reingold S.C., Sandberg-Wollheim M., Sibley W., Thompson A., van den Noort S., Weinshenker B.Y., Wolinsky J.S. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001, 50:121-127.
24. Nakamura M., Houzen H., Niino M., Tanaka K., Sasaki H. Relationship between Barkhof criteria and the clinical features of multiple sclerosis in northern Japan. Mult Scler 2009, 15:1450-1458.
25. Nejentsev S., Cooper J.D., Godfrey L., Howson J.M., Rance H., Nutland S., Walker N.M., Guja C., Ionescu-Tirgovişte C., Savage D.A., Undlien D.E., Rønningen K.S., Tuomilehto-Wolf E., Tuomilehto J., Gillespie K.M., Ring S.M., Strachan D.P., Widmer B., Dunger D., Todd J.A. Analysis of the vitamin D receptor gene sequence variants in type 1 diabetes. Diabetes 2004, 53:2709-2712.
26. O'Riordan J.I., Gallagher H.L., Thompson A.J., Howard R.S., Kingsley D.P., Thompson E.J., McDonald W.I., Miller D.H. Clinical, CSF, and MRI findings in Devic's neuromyelitis optica. J Neurol Neurosurg Psychiatry 1996, 60:382-387.
27. Panitch H.S., Hirsch R.L., Schindler J., Johnson K.P. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology 1987, 37:1097-1102.
28. Petereit H.F., Nolden S., Schoppe S., Bamborschke S., Pukrop R., Heiss W.D. Low interferon gamma producers are better treatment responders: a two-year follow-up of interferon beta-treated multiple sclerosis patients. Mult Scler 2002, 8:492-494.
29. Polman C.H., Reingold S.C., Banwell B., Clanet M., Cohen J.A., Filippi M., Fujihara K., Havrdova E., Hutchinson M., Kappos L., Lublin F.D., Montalban X., O'Connor P., Sandberg-Wollheim M., Thompson A.J., Waubant E., Weinshenker B., Wolinsky J.S. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011, 69:292-302.
30. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C., Johnson K.P., Sibley W.A., Silberberg D.H., Tourtellotte W.W. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983, 13:227-231.
31. Ribeiro M.A., Cabral H.O., Costa P.F. Modulatory effect of NO on sodium currents in a neuroblastoma cell line: aspects of cell specificity. Neurosci Res 2007, 58:361-370.
32. Semino C., Angelini G., Poggi A., Rubartelli A. NK/iDC interaction results in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1. Blood 2005, 106:609-616.
33. Shi Y., Sandoghchian Shotorbani S., Su Z., Liu Y., Tong J., Zheng D., Chen J., Liu Y., Xu Y., Jiao Z., Wang S., Lu L., Huang X., Xu H. Enhanced HMGB1 expression may contribute to Th17 cells activation in rheumatoid arthritis. Clin Dev Immunol 2012, 2012:295081.
34. Shimizu J., Hatanaka Y., Hasegawa M., Iwata A., Sugimoto I., Date H., Goto J., Shimizu T., Takatsu M., Sakurai Y., Nakase H., Uesaka Y., Hashida H., Hashimoto K., Komiya T., Tsuji S. IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology 2010, 75:1423-1427.
35. Strachan M.W., Reynolds R.M., Frier B.M., Mitchell R.J., Price J.F. The relationship between type 2 diabetes and dementia. Br Med Bull 2008, 88:131-146.
36. Uesugi H., Ozaki S., Sobajima J., Osakada F., Shirakawa H., Yoshida M., Nakao K. Prevalence and characterization of novel pANCA, antibodies to the high mobility group non-histone chromosomal proteins HMG1 and HMG2, in systemic rheumatic diseases. J Rheumatol 1998, 25:703-709.
37. Wang H., Bloom O., Zhang M., Vishnubhakat J.M., Ombrellino M., Che J., Frazier A., Yang H., Ivanova S., Borovitkova L., Manogue K.R., Faist E., Abraham E., Andersson J., Andersson U., Molina P.E., Abumrad N.N., Sama A., Tracey K.J. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999, 285:248-251.
38. Wang K.C., Tsai C.P., Lee C.L., Chen S.Y., Chen S.J. The prevalence of long spinal cord lesions and anti-aquaporin 4 antibodies in neuromyelitis optica patients in Taiwan. Eur Neurol 2011, 65:99-104.
39. Wingerchuk D.M., Hogancamp W.F., O'Brien P.C., Weinshenker B.G. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999, 53:1107-1114.
40. Wingerchuk D.M., Lennon V.A., Pittock S.J., Lucchinetti C.F., Weinshenker B.G. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006, 66:1485-1489.
41. Wittemann B., Neuer G., Michels H., Truckenbrodt H., Bautz F.A. Autoantibodies to nonhistone chromosomal proteins HMG-1 and HMG-2 in sera of patients with juvenile rheumatoid arthritis. Arthritis Rheum 1990, 33:1378-1383.
42. 25- T cells of spleen in mice. Chin J Surg 2008, 46:217-220. (in Chinese).